What are the latest funding news in the AI in drug discovery market? (September 2026)
Download our beautiful pitch about the AI in drug discovery market
In our AI in drug discovery market deck, you will find everything you need to understand the market
From March 3 through July 22, 2026, we identified 12 publicly announced financings that clearly fit the AI in drug discovery market definition.
These deals represented approximately $2.64 billion in disclosed funding, although the total was heavily shaped by two exceptionally large growth rounds.
No clearly qualifying pure-play financing announced after July 22 and before September 2, 2026 was identified in the information reviewed.
And if you want to better understand this new industry, you can download our pitch covering the AI in drug discovery market.
Insights
- Isomorphic Labs and Chai Discovery accounted for about 95% of the $2.64 billion disclosed in this AI in drug discovery funding list, showing how late-stage platform rounds can distort market-wide averages.
- The median-sized deal was far smaller than the average, as 10 of the 12 financings were below $50 million despite the market's multi-billion-dollar headline total.
- Half of the companies raised seed or pre-seed rounds, indicating that new AI drug discovery infrastructure is still being formed across molecular design, target discovery and toxicology.
- Proprietary biological data was a recurring investment theme, from Sightera's patient-derived models to Transcripta's transcriptomic signatures and DeepCyte's single-cell metabolomics.
- Several companies combined software with internal therapeutic programs, suggesting investors increasingly value AI drug discovery platforms that can prove their models through real preclinical assets.
- Small-molecule discovery remained the broadest category, while antibody design, protein characterization and AI toxicology showed that capital is spreading across more specialized discovery workflows.
- European companies featured prominently in the list, with financings in Belgium, France and the United Kingdom alongside major rounds from companies based in the United States.
As this chart shows, and as featured in our AI in drug discovery market deck, search interest in AI drug discovery has grown rapidly
Summary table of the latest funding deals in the AI in drug discovery market as of September 2026
We define the AI in drug discovery market as revenue from AI-enabled software and related services that materially support the identification and design of therapeutic candidates before human trials.
We include AI used for target identification/validation, hit/lead generation, lead optimization, de novo design, repurposing, and preclinical prediction/assessment, including ADMET and toxicology.
We exclude AI primarily used for clinical trial operations, regulatory submissions, manufacturing, pharmacovigilance, or commercial and enterprise analytics not directly tied to discovery and preclinical candidate selection.
You can also read our detailed analysis to understand how funding activity in the AI in drug discovery market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the AI in drug discovery market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Transcripta Bio | July 22, 2026 | $24M | Post-Series A financing | Drug Repurposing & Lead Optimization |
| Sightera Biosciences | July 17, 2026 | ~$3.5M | Pre-seed | Small-Molecule Design & Candidate Selection |
| Chai Discovery | July 14, 2026 | $400M | Series C | Biologic Design & Lead Generation |
| Isomorphic Labs | May 12, 2026 | $2.1B | Series B | Molecular Design & Lead Optimization |
| Fathom Therapeutics | April 27, 2026 | $47M | Series A | Small-Molecule Design & Lead Optimization |
| 10x Science | April 22, 2026 | $4.8M | Seed | Protein Characterization & Candidate Selection |
| Helical | April 14, 2026 | $10M | Seed | Target Discovery & Therapeutic Design |
| DeepCyte | April 9, 2026 | $1.5M | Seed | AI Toxicology & Preclinical Safety Assessment |
| Generare | April 2, 2026 | ~$23M | Series A | Genome Mining & Hit Generation |
| RyboDyn | March 24, 2026 | $10M | Seed | Target Identification & Validation |
| Ternary Therapeutics | March 17, 2026 | ~$4.5M | Seed | Molecular-Glue Design & Lead Generation |
| Antiverse | March 3, 2026 | $9.3M | Series A | Antibody Design & Lead Optimization |
All the latest funding deals during in the AI in drug discovery market as of September 2026
Transcripta Bio reported $24M in funding in July 2026.
When was it?
Transcripta Bio announced the financing on July 22, 2026.
Who are they?
Transcripta Bio uses patient-derived transcriptomic data and machine learning to identify drug candidates that can reverse disease signatures in neurological and neuromuscular disorders.
Geographical focus?
Transcripta Bio is based in Palo Alto, California, and develops programs for global clinical development.
Why do we include them in the AI in drug discovery market?
Transcripta Bio belongs in this market because its platform supports drug repurposing, lead optimization and preclinical candidate selection.
What is the company stage?
Transcripta Bio is at an advanced preclinical stage, with several programs in candidate selection or IND-enabling work.
How much did they raise?
Transcripta Bio reported $24 million raised since its Series A financing.
What round is it?
Transcripta Bio described the transaction as post-Series A financing rather than as a separately named round.
Why did they raise?
Transcripta Bio raised the capital to fund IND-enabling studies and clinical preparation for its autism-spectrum-disorder and FSHD programs.
Sightera Biosciences raised about $3.5M in July 2026.
When was it?
Sightera Biosciences announced its pre-seed financing on July 17, 2026.
Who are they?
Sightera Biosciences uses patient-derived disease models, high-throughput screening and AI to design small-molecule therapies for oncology and fibrosis.
Geographical focus?
Sightera Biosciences is based in Antwerp, Belgium, and is building pharmaceutical and biotechnology partnerships internationally.
Why do we include them in the AI in drug discovery market?
Sightera Biosciences belongs in this market because its AI platform designs molecules and selects preclinical candidates from patient-derived drug-response data.
What is the company stage?
Sightera Biosciences is a pre-seed company with a platform and a lead molecular-glue program progressing toward candidate selection.
How much did they raise?
Sightera Biosciences raised €3 million, equivalent to roughly $3.5 million.
What round is it?
Sightera Biosciences raised a pre-seed round led by Entourage, Anacura and QBIC.
Why did they raise?
Sightera Biosciences raised the funding to scale its platform, expand its team and advance its oncology program toward preclinical candidate selection.
This chart, featured in our AI in drug discovery market deck, compares the main business model options for AI drug discovery biotech companies
Chai Discovery raised $400M in a July 2026 Series C.
When was it?
Chai Discovery announced the Series C financing on July 14, 2026.
Who are they?
Chai Discovery develops generative AI models that help scientists design antibodies, proteins and other therapeutic molecules from scratch.
Geographical focus?
Chai Discovery is based in San Francisco and serves pharmaceutical and biotechnology companies globally.
Why do we include them in the AI in drug discovery market?
Chai Discovery belongs in this market because its models support structural reasoning, molecular generation and binding prediction for biologic drug design.
What is the company stage?
Chai Discovery is in rapid growth and early commercial scale, with deployments at major pharmaceutical companies.
How much did they raise?
Chai Discovery raised $400 million at a reported $3.8 billion valuation.
What round is it?
Chai Discovery raised a Series C led by Index Ventures.
Why did they raise?
Chai Discovery raised the capital to improve its models, expand commercial deployment and support more AI-designed therapeutic programs.
Isomorphic Labs raised $2.1B in a May 2026 Series B.
When was it?
Isomorphic Labs announced the financing on May 12, 2026.
Who are they?
Isomorphic Labs develops predictive and generative AI systems for designing small-molecule and biologic medicines.
Geographical focus?
Isomorphic Labs operates from London and Lausanne while working with pharmaceutical partners worldwide.
Why do we include them in the AI in drug discovery market?
Isomorphic Labs belongs in this market because its drug design engine supports molecular design, interaction prediction and therapeutic lead optimization.
What is the company stage?
Isomorphic Labs is a growth-stage company with major pharmaceutical collaborations and an advanced preclinical pipeline.
How much did they raise?
Isomorphic Labs raised $2.1 billion in new capital.
What round is it?
Isomorphic Labs raised a Series B led by Thrive Capital.
Why did they raise?
Isomorphic Labs raised the funding to scale its AI drug design engine, expand globally and progress its therapeutic programs toward the clinic.
This chart, featured in our AI in drug discovery market deck, shows how Shrödinger is positioned in AI drug discovery
Fathom Therapeutics raised $47M in an April 2026 Series A.
When was it?
Fathom Therapeutics announced the oversubscribed financing on April 27, 2026.
Who are they?
Fathom Therapeutics uses quantum chemistry, physics simulations and AI to design small molecules that behave predictably inside living cells.
Geographical focus?
Fathom Therapeutics operates from New York and Boston and targets diseases with broad international relevance.
Why do we include them in the AI in drug discovery market?
Fathom Therapeutics belongs in this market because its platform performs AI-enabled small-molecule design, hit generation and lead optimization.
What is the company stage?
Fathom Therapeutics is at a validated preclinical and early growth stage with internal discovery programs.
How much did they raise?
Fathom Therapeutics raised $47 million.
What round is it?
Fathom Therapeutics raised an oversubscribed Series A led by Sutter Hill Ventures.
Why did they raise?
Fathom Therapeutics raised the capital to expand lab-in-the-loop capabilities and advance internal programs in high-impact diseases.
10x Science raised $4.8M in a seed round in April 2026.
When was it?
10x Science announced the seed round on April 22, 2026.
Who are they?
10x Science uses chemistry-aware AI to interpret mass-spectrometry data and characterize protein therapeutics for drug development teams.
Geographical focus?
10x Science is based in the San Francisco Bay Area and serves pharmaceutical, biotechnology and research customers.
Why do we include them in the AI in drug discovery market?
10x Science belongs in this market because its software supports protein characterization, candidate prioritization and early development-risk assessment.
What is the company stage?
10x Science is an early product and customer-validation company with pharmaceutical and academic users.
How much did they raise?
10x Science raised $4.8 million.
What round is it?
10x Science raised a seed round led by Initialized Capital.
Why did they raise?
10x Science raised the funding to hire engineers and commercialize software that helps teams evaluate growing numbers of AI-generated protein candidates.
In our AI in drug discovery market deck, we identify pain points entrepreneurs should prioritize
Helical raised $10M in a seed round in April 2026.
When was it?
Helical announced the seed financing on April 14, 2026.
Who are they?
Helical provides a virtual AI laboratory that helps biopharma teams run target discovery, biomarker discovery and therapeutic design workflows.
Geographical focus?
Helical is based in London and serves pharmaceutical companies across global R&D markets.
Why do we include them in the AI in drug discovery market?
Helical belongs in this market because its platform helps users identify, rank and validate discovery candidates before clinical development.
What is the company stage?
Helical is at an early growth stage, with pharmaceutical deployments and a focus on product-market fit.
How much did they raise?
Helical raised $10 million.
What round is it?
Helical raised a seed round led by redalpine.
Why did they raise?
Helical raised the capital to deepen pharmaceutical deployments, broaden therapeutic coverage and strengthen its evidence layer.
DeepCyte raised $1.5M in seed funding in April 2026.
When was it?
DeepCyte launched and announced its financing on April 9, 2026.
Who are they?
DeepCyte combines single-cell metabolomics and AI to predict, explain and classify drug toxicity in human cells.
Geographical focus?
DeepCyte operates through United States and Denmark entities and sells to biopharmaceutical teams internationally.
Why do we include them in the AI in drug discovery market?
DeepCyte belongs in this market because its technology supports preclinical toxicology and safety assessment before candidates enter human trials.
What is the company stage?
DeepCyte is at an early validation stage with product development and early-access commercialization underway.
How much did they raise?
DeepCyte raised $1.5 million.
What round is it?
DeepCyte raised seed funding, with investors not publicly identified in the announcement.
Why did they raise?
DeepCyte raised the funding to develop and commercialize its single-cell data platform and AI toxicology products.
This market map, featured in our AI in drug discovery market deck, highlights top companies and startups in the AI in drug discovery market
Generare raised about $23M in an April 2026 Series A.
When was it?
Generare announced the Series A financing on April 2, 2026.
Who are they?
Generare decodes microbial genomes to create molecular data and discover previously unknown drug-like small molecules.
Geographical focus?
Generare is based in Paris, France, and serves life-sciences companies internationally.
Why do we include them in the AI in drug discovery market?
Generare belongs in this market because its genome-mining, synthetic-biology and computational platform supports hit generation and small-molecule lead discovery.
What is the company stage?
Generare is at a scale-up stage with commercial customers and a growing library of characterized compounds.
How much did they raise?
Generare raised €20 million, equivalent to approximately $23 million.
What round is it?
Generare raised a Series A co-led by Alven and Daphni.
Why did they raise?
Generare raised the funding to scale its proprietary molecular dataset and increase discovery capacity for pharmaceutical customers.
RyboDyn raised $10M in seed financing in March 2026.
When was it?
RyboDyn announced the initial close of its seed financing on March 24, 2026.
Who are they?
RyboDyn combines novel RNA sequencing and AI to uncover hidden cancer antigens and develop new immunotherapy targets.
Geographical focus?
RyboDyn is based in San Diego and initially focuses on oncology programs with global therapeutic potential.
Why do we include them in the AI in drug discovery market?
RyboDyn belongs in this market because its platform identifies and validates therapeutic targets in the dark transcriptome and proteome.
What is the company stage?
RyboDyn is a seed-stage preclinical company moving from platform validation toward IND-enabling programs.
How much did they raise?
RyboDyn raised $10 million in the initial close.
What round is it?
RyboDyn raised a seed financing backed by a syndicate of new and existing investors.
Why did they raise?
RyboDyn raised the capital to expand its target atlas, validate cancer targets and advance early programs into IND-enabling studies.
This chart, featured in our AI in drug discovery market deck, shows annual funding in AI drug discovery startups
Ternary Therapeutics raised about $4.5M in March 2026.
When was it?
Ternary Therapeutics announced the financing on March 17, 2026.
Who are they?
Ternary Therapeutics uses physics-informed AI, molecular dynamics and laboratory feedback to design molecular-glue medicines.
Geographical focus?
Ternary Therapeutics is based in London and initially focuses on inflammatory and neuroinflammatory disease programs.
Why do we include them in the AI in drug discovery market?
Ternary Therapeutics belongs in this market because its platform supports molecular-glue target assessment, virtual screening and lead optimization.
What is the company stage?
Ternary Therapeutics is a seed-stage company moving from platform development into preclinical therapeutic programs.
How much did they raise?
Ternary Therapeutics raised €4.1 million, equivalent to approximately $4.5 million.
What round is it?
Ternary Therapeutics raised a seed round led by daphni.
Why did they raise?
Ternary Therapeutics raised the capital to scale its AI platform, recruit scientific talent and advance molecular-glue programs.
Antiverse raised $9.3M in a March 2026 Series A.
When was it?
Antiverse announced the Series A financing on March 3, 2026.
Who are they?
Antiverse uses generative machine learning and laboratory validation to design therapeutic antibodies for difficult biological targets.
Geographical focus?
Antiverse is headquartered in Cardiff, Wales, has a Boston presence and works with pharmaceutical partners internationally.
Why do we include them in the AI in drug discovery market?
Antiverse belongs in this market because its platform generates and optimizes therapeutic antibody sequences for early drug programs.
What is the company stage?
Antiverse is at a validated preclinical and early growth stage, with lead programs progressing toward in-vivo efficacy studies.
How much did they raise?
Antiverse raised $9.3 million.
What round is it?
Antiverse raised a Series A led by Soulmates Ventures.
Why did they raise?
Antiverse raised the funding to scale its antibody-discovery platform, advance its internal pipeline and expand pharmaceutical collaborations.
Related blog posts
- The evolution of funding activity in AI for drug discovery
- The main fundraising trends in AI for drug discovery
- How strong is fundraising in the AI in drug discovery market right now?
- AI in Drug Discovery: what are the top startups?
